SOLID TUMORS

This early-stage study tested a new cancer drug called RS-0139 to find a safe dose and see how the body processes it. It involved 16 adults with advanced solid tumors that had returned or spread and who had no other standard treatments left. The main goal was to check for serious…

This early-stage study tested a new oral drug called TdCyd in adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and see how the drug works in the body. Researchers hoped the drug might slow tumor growth b…

This early-stage study tested the safety and initial effects of a new combination immune cell therapy for patients with advanced solid tumors that have spread and no longer respond to standard treatments. The trial involved 9 participants and aimed to find a safe dose and treatme…

This study tested whether an oral medicine called BI 907828 could help control advanced cancers of the bile duct, pancreas, lung, or bladder that had a specific genetic pattern (MDM2 amplified, TP53 wild-type) and had stopped responding to standard treatments. All 99 participants…

This study tested a new drug, CFT1946, for people with advanced solid tumors that have a specific genetic change called BRAF V600. The main goals were to find a safe dose and see if the drug, given alone or with other medications, could help control the cancer. It involved 89 adu…

This early-stage trial tested whether combining two cancer drugs—nilotinib and paclitaxel—is safe for people with advanced solid tumors that haven't responded to standard treatments. Researchers enrolled 47 adults and some teenagers to find the highest dose that could be given sa…

This early-stage study tested the safety and dosing of a new drug called ulevostinag, which is injected directly into tumors. It was tested alone and combined with the immunotherapy drug pembrolizumab in 156 people with advanced or spreading solid tumors or lymphomas. The main go…

This early-stage study tested a new experimental immunotherapy drug called eciskafusp alfa. Researchers gave it to 189 adults with advanced solid tumors, both by itself and combined with an existing drug (atezolizumab), to check its safety and find the right dose. The main goals …

This study tested a new drug called bemarituzumab in adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety and see if it could shrink tumors. Researchers enrolled 260 people with various cancers, inclu…

This first-in-human study tested a new drug called DF6002 in 170 patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find safe dose levels and see if the drug, given alone or with an existing immunotherapy (nivolumab), co…

This small, early-stage study tested a new cell therapy for patients with advanced solid tumors that had stopped responding to standard treatments. Doctors collected immune cells from patients, modified them in a lab to target a specific protein (ALPP) found on their tumors, and …

This study aimed to find the safest dose for using two existing cancer drugs, dasatinib and bevacizumab, together. It involved 50 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to understand the side effects of this drug co…

This early-phase study tested a new oral drug called revumenib (SNDX-5613) in 42 adults with advanced colorectal cancer or other solid tumors that had worsened despite at least one prior treatment. The main goals were to find a safe dose, see how the body processes the drug, and …

This early-stage study tested a new immune therapy for children and young adults whose solid tumors did not respond to standard treatments. Doctors collected and grew a patient's own 'natural killer' (NK) immune cells, then gave them back to the patient to fight the cancer. The m…

This study tested whether statin drugs, commonly used for cholesterol, could reduce hearing loss caused by platinum-based chemotherapy. It involved 56 patients with solid tumors who were receiving this type of chemo. The goal was to see if adding a statin could protect their hear…

This study aimed to understand and improve the management of bone pain, a frequent side effect of a drug (G-CSF) given to support patients during chemotherapy for solid tumors. Researchers observed 128 patients to see how different pain relief methods, like painkillers and other …

This study tested tumor samples from 470 cancer patients to identify specific biological markers in their cancer cells. The goal was to use this information to determine which patients might qualify for future Roche treatment trials. The study did not provide treatment itself but…

This study tested whether smartphones and smartwatches could be used to reliably measure symptoms like fatigue and changes in activity in cancer patients. Researchers enrolled 49 adults with various cancers who were already receiving treatment. They used iPhones and Apple Watches…

This early study tested a new cancer drug called BI 907828 in adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to see if taking common medications (an antibiotic or an antifungal) at the same time changed how much of the canc…

This early-phase study examined how the cancer drug belinostat is processed by the body in patients with advanced solid tumors or blood cancers that have returned or stopped responding to treatment. Researchers specifically looked at how different genetic variations affect drug p…

This French study asked cancer patients how satisfied they were with their care when switching from receiving immunotherapy at a hospital to receiving it at home. Researchers surveyed 49 adults with solid tumors who were already approved for home treatment. The goal was to unders…

This study explored whether artificial intelligence (AI) could be trained to detect and classify pain in cancer patients by analyzing their facial expressions and voice patterns. Researchers enrolled 83 people aged 12 and older who were undergoing cancer treatment. Over three mon…